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Senile plaques consisting of b-amyloid (Ab) and
neurofibrillary tangles composed of hyperphos-
phorylated tau are major pathological hallmarks of
Alzheimer’s disease (AD). Elucidation of factors that
modulate Ab generation and tau hyperphosphoryla-
tion is crucial for AD intervention. Here, we identify
a mouse gene Rps23r1 that originated through retro-
position of ribosomal protein S23. We demonstrate
that RPS23R1 protein reduces the levels of Ab and
tau phosphorylation by interacting with adenylate
cyclases to activate cAMP/PKA and thus inhibit
GSK-3 activity. The function of Rps23r1 is demon-
strated in cells of various species including human,
and in transgenic mice overexpressing RPS23R1.
Furthermore, the AD-like pathologies of triple trans-
genic AD mice were improved and levels of synaptic
maker proteins increased after crossing them with
Rps23r1 transgenic mice. Our studies reveal a new
target/pathway for regulating AD pathologies and
uncover a retrogene and its role in regulating protein
kinase pathways.
INTRODUCTION
Alzheimer’s disease (AD) is featured by extracellular neuritic
plaques, intracellular neurofibrillary tangles (NFTs), synaptic
dysfunctions, and neural degeneration in vulnerable brain regions
(Tanzi and Bertram, 2005). Neuritic plaques are composed of
aggregates of heterogeneous b-amyloid (Ab) peptides, which
are derived from b-amyloid precursor protein (APP) through
sequential cleavages by b-secretase (BACE1) and the g-secre-
tase complex (consisting of at least four components: presenilin,328 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.nicastrin, APH-1, and PEN-2) (Cole and Vassar, 2007; De
Strooper, 2003; Zhang and Xu, 2007). Multiple lines of evidence
suggest that overproduction/aggregation of Ab in the brain is
a causative factor for AD pathogenesis (Hardy and Selkoe,
2002). NFTs are composed of hyperphosphorylated microtu-
bule-associated protein tau (Buee et al., 2000; Lee et al., 2001).
Numerous studies have shown that pathogenic APP metabo-
lism/Ab generation and tau phosphorylation are highly regulated
via various signal transduction pathways, e.g., protein kinases
and phosphatases (Buxbaum et al., 1994; Fang et al., 2000;
Xu et al., 1996) and steroid and peptide hormones (Gasparini
et al., 2001; Xu et al., 1998). Among these regulatory pathways,
glycogen synthase kinase-3 (GSK-3, a and b isoforms),
a serine/threonine kinase essential for a variety of cellular func-
tions including cell adhesion, cell division, transcription (Frame
and Cohen, 2001), has been demonstrated to regulate both Ab
generation and tau phosphorylation (Flaherty et al., 2000; Phiel
et al., 2003). This unique feature renders manipulation of GSK-3
activity an attractive therapeutic approach for AD (Frame and
Cohen, 2001; Martinez et al., 2002; Medina and Castro, 2008).
Hence identification of new genes involved in these processes
will be instrumental in developing novel AD therapeutics.
The creation of genetic novelty by the formation of new genes
has an important role in evolution. New genes can originate
through different mechanisms that include exon shuffling, gene
duplication, gene fusion/fission, mobile element integration,
lateral gene transfer, and retroposition (Long et al., 2003).
Retroposition is a process in which a parental mRNA is reverse-
transcribed and inserted into the organism’s genome, creating
duplicate genes in new genomic positions (Hollis et al., 1982;
Karin and Richards, 1982; Ueda et al., 1982). Although these
intronless retroposed gene copies commonly lack the regulatory
elements of parental genes and thus routinely have been classi-
fied as processed pseudogenes (Jeffs and Ashburner, 1991;
Mighell et al., 2000; Zhang et al., 2004), occasionally, these retro-
posed gene copies can recruit regulatory elements as well as
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Rps23r1 Ameliorates AD-like PathologiesFigure 1. Genetic Screening Using Random
Homozygous Gene Perturbation (RHGP)
(A) The new RHGP gene search vector has a tetra-
cycline-regulated element (TRE) regulated CMV
promoter, which drives expression of the puro-
mycin N-acetyl-transferase gene (Pac), a plasmid
replication origin and a chloramphenicol resis-
tance marker (Ori-CAT), and a LoxP site in the
30LTR. In addition, there is a Cre recombinase
gene (Cre) between the 50LTR and the 30LTR.
(B) The initial provirus randomly inserted into chro-
mosomes of mammalian cells upon retroviral
infection.
(C) The final integrated provirus after the expres-
sion of the Cre recombinase in the initial provirus,
which mediates DNA recombination at the loxP
sites.
(D) Strategy for screening for Ab-reducing genes in
N2aSwe cells with RHGP vector integration.protein-encoding sequences at or near the retroposition site and
become expressed and functional (Babushok et al., 2007; Kaess-
mann et al., 2009; Long et al., 2003; Vinckenbosch et al., 2006).
Nevertheless, studies to elucidate the functions of these newly
originated genes, especially the functions related to diseases,
are limited (Kaessmann et al., 2009; Vinckenbosch et al., 2006).
Random homozygous gene perturbation (RHGP; previously
called random homozygous knockout, RHKO) is a genome-
wide genetic approach that identifies genes based on their
biological functions (Li and Cohen, 1996; Liu et al., 1999,
2000a, 2000b). The design of RHGP enables either reduced or
increased expression of chromosomal genes near the incorpora-
tion site of the gene search vector cassette that contains a regu-
lated promoter. This strategy has been used successfully to
identify genes whose functional homozygous inactivation leads
to reversible tumorigenesis (Li and Cohen, 1996; Liu et al.,
1999, 2000a, 2000b) or altered sensitivity to chemotherapeutic
agents (Lih et al., 2006).
Here, using the RHGP approach, we identified a geneRps23r1
that originated through retroposition of the mouse ribosomal
protein S23 (Rps23) mRNA. The Rps23r1 gene is reversely tran-
scribed relative to its parental gene, expressing a structurally
unrelated yet functional protein RPS23R1. More importantly,
we demonstrated both in vitro and in vivo that overexpression
of the RPS23R1 protein decreases the levels of Ab and tau
phosphorylation and increases synaptic marker proteins in AD
transgenic mice by inhibiting GSK-3 activity via the adenylate
cyclase/ protein kinase A (PKA) pathway.
RESULTS
Genome-wide Screening for Genes that Regulates Ab
Generation
It has been shown that reduction of Ab levels is accompanied
by cell-surface accumulation of APP bCTF (the product ofb-cleavage and immediate substrate for g-cleavage), which is
readily detectable in cells deficient in PS1 (Chen et al., 2000),
and these cells can be identified using an antibody specifically
recognizing the N terminus of APP bCTF (FCA18) (Ancolio
et al., 1999). Based on this observation, we adapted RHGP as
a high throughput screen to search for genes that regulate Ab
generation.
We modified the original vector pLLGSV (Li and Cohen, 1996)
to increase efficiency of retroviral integration and gene recovery.
The new RHGP gene search vector contains modified LTRs and
utilizes the Cre-LoxP mediated recombination to minimize
promoter interference in provirus and to facilitate genomic
DNA cloning (Figure 1A). This vector was transfected into
Phoenix-Ampho cells for viral packaging. Harvested retrovirus
was used to infect mouse neuroblastoma N2a cells stably
expressing the human APP Swedish mutation (N2aSwe). After
random insertion, the provirus (Figure 1B) expressed Cre recom-
binase for recognition and recombination of the two LoxP
sites located in the 50LTR and 30LTR, respectively, generating
the final integrated provirus (Figure 1C). A tetracycline regulated
promoter (TRE-CMV) promoter in the final integrated provirus
drives the expression ofPac for puromycin selection and initiates
transcription into flanking chromosomal gene that can either
overexpress, when TRE-CMV is in the same orientation, or
suppress (by expressing antisense transcripts) when TRE-CMV
is in the opposite orientation relative to the flanking gene.
Moreover, transcription of the tetracycline-regulated (tet-off)
transactivator was reversed in the presence of tetracycline (or
doxycycline).
Therefore, we first acquired N2aSwe cells with stable integra-
tion of the RHGP search vector by puromycin selection. These
cells were live-immunostained with fluorescently labeled
FCA18 antibody followed by multiple rounds of FACS sorting
to enrich for cells showing surface APP bCTF accumulation.
Less than 0.1% of cells showing bCTF accumulation after firstNeuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc. 329
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Rps23r1 Ameliorates AD-like PathologiesFigure 2. Identification of the FG01 Cell Clone
(A) RHGP libraries of N2aSwe cells were live-immunostained for cell surface bCTF using an Ab N-terminal specific antibody (FCA18) (Barelli et al., 1997) and
screened by multiple rounds of FACS sorting. Less than 0.1% of cells showing bCTF accumulation after first round of FACS sorting were enriched up to 75%
following another two rounds of FACS sorting. y axis, cell number; x axis, fluorescence intensity.
(B) Parental N2aSwe cells (I and III) and one cell clone derived from FACS sorting, FG01 (II and IV), were live immunostained to visualize surface APP bCTF (red,
I and II). Cells were also double immunostained with FITC-VVA (Vicia Vilosa Agglutinin, Vector Laboratories) to stain total surface glycoproteins (III and IV).
(C) Parental N2aSwe and FG01 cells were treated with or without 2 mg/ml doxycycline (DOX) for 72 hr. Equal amounts of cell lysates were subjected to SDS-PAGE
and western blot to detect full-length APP and bCTFs. Secreted Ab was immunoprecipitated from conditioned media and analyzed by western blot. Levels of
these proteins in FG01 cells were quantified by densitometry and normalized to those in controls for comparison (set as one arbitrary unit).
(D) Parental N2aSwe and FG01 cells were treated with 2 mg/ml doxycycline (+) or DMSO () for 72 hr before RNA was isolated for real-time reverse transcription-
PCR to quantify Rps23r1 expression. The level of Rps23r1 in N2aSwe cells treated with DMSO was used as normalization controls (set as one arbitrary unit).
*p < 0.05. p values were calculated using two-tailed Student’s t test (n = 3). Error bars, SEM.round of FACS sorting were enriched up to 75% following
another two rounds of FACS sorting (Figure 2A). These cells
were then sorted with additional FACS in the presence of doxy-
cycline for a reversion of cell surface APP bCTF to background
level to eliminate potential false positive. The final sorted cells
were cloned individually, propagated and assayed for both
accumulated cell surface APP bCTF and reduced Ab generation.
This screening strategy is shown in Figure 1D.
Identification of the Rps23r1 Gene
One clone, FG01, was isolated for the high level of cell-surface
APP bCTF and the significant reduction of Ab secretion (Figures
2B and 2C). Both phenotypes were reversed by doxycycline
treatment, validating that the effects were indeed a result of
RHGP rather than cell-cell/clonal variation in APP/bCTF expres-
sion or any random mutagenesis (Figure 2C). Subcloning
and sequence analyses revealed that the RHGP vector was
inserted into chromosome 8 at a site 1.2 kb upstream of the330 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.C330021F23Rik gene (GenBank ID: 546049), which has no
known function. We herein designated this gene as Rps23r1
based on its origination (see below). The upstream location
and the same orientation of the inserted RHGP vector strongly
suggested that Rps23r1 was likely overexpressed in the FG01
cell clone. This notion was supported by real-time reverse tran-
scription-PCR (RT-PCR) using RNAs from parental N2aSwe
and the FG01 RHGP cell clone, which showed that Rps23r1
was overexpressed in the FG01 RHGP cell clone and its overex-
pression was reversed by doxycycline treatment (Figure 2D).
The Rps23r1 gene is predicted to encode a 141 amino
acid-long hypothetical protein that we designate RPS23R1.
Interestingly, analyses of multiple genome databases (GenBank,
UCSC Genome Browser, and Ensemble Genome Browser) with
the RPS23R1 protein sequence identified another three homolo-
gous proteins in mice but no obvious homologs in humans and
rats (data not shown). Further analysis with the Rps23r1 gene
sequence showed that the predominant protein-encoding region
Neuron
Rps23r1 Ameliorates AD-like PathologiesFigure 3. The Rps23r1 Gene Originated Through Retroposition of the Mouse Rps23 mRNA
(A) Sequence alignment of the reverse and complementary (RC) sequence of mouse Rps23 (mRps23) mRNA with the Rps23r1 sequence. Small letters indicate
intron sequence (in green) or untranslated regions of the exon (in red). Capital letters indicate protein-encoding sequence (in blue). Additional gene parts of
Rps23r1 recruited from integrated chromosomal sites were indicated by lines (for introns) and boxes (for exons) (not drawn to proportion). The colors red, green,
and blue indicate exons, introns, and protein-encoding regions, respectively. *nonconserved nucleotide residues.
(B) Phylogenetic relationships of Rps23r1 and human, rat, and mouse Rps23 genes (hRps23, rRps23, and mRps23) based on their sequence identity to mRps23
within the homologous region.of the Rps23r1 gene was highly homologous to the reverse and
complementary sequence of the mouse ribosomal protein S23
(Rps23) mRNA (Figure 3A). The similarity between Rps23r1 and
mouse Rps23 was even higher than those between mouse
Rps23 and rat or human Rps23 (Figure 3B), suggesting that
Rps23r1 originated from mouse Rps23 after the divergence of
mice and rats. New genes can originate through different mech-
anisms (Long et al., 2003). However, the presence of the mouse
Rps23 untranslated regions (UTRs) and the absence of the
mouse Rps23 introns in the homologous regions between
Rps23r1 and mouse Rps23 clearly suggest that Rps23r1 origi-
nated through retroposition of the mouse Rps23 mRNA, which
recruited regulatory units and additional protein-encoding
sequence near the retroposition site. But transcription of
Rps23r1 is reversed compared to Rps23. To search for human
homologs of Rps23r1, we scanned the human genome with
the human Rps23 cDNA sequence and identified several
Rps23 retroposition sites (see Figure S1 available online).
However, computational gene prediction of these sites revealed
no functional Rps23r1-like genes. We also carried out RT-PCR
with primers binding regions right next to these human Rps23
retroposition sites and failed to obtain positive amplification
(data not shown).
RPS23R1 Is a Type Ib Transmembrane Protein
Bioinformatics analysis using the RPS23R1 amino acid
sequence predicted a helical transmembrane domain near theC terminus but no obvious signal peptide sequence. We con-
structed a vector expressing recombinant RPS23R1 with
a Myc tag at the N terminus and a His6 tag at the C terminus
(Myc-RPS23R1-His6; Figure 4A). Both Myc and His6 antibodies
recognized a product of approximately 17 kDa in transfected
Myc-RPS23R1-His6 cells, consistent with the predicted molec-
ular weight, indicating that there is no cleavable signal peptide
sequence within RPS23R1 (Figure 4B). Furthermore, after trans-
fection of Myc-RPS23R1-His6 vector into N2a cells, fractionation
of cell lysates into cytosolic and membrane components
indicated that the majority of RPS23R1 protein was located
in membrane fractions (Figure 4C). Biotinylation assays also
revealed that RPS23R1 was delivered to the cell surface
(Figure 4D). To determine RPS23R1 topology, we transfected
N2a cells with the Myc-RPS23R1-His6 vector and immuno-
stained either live cells or cells after permeabilization, using
antibodies against Myc or His6. Our results show that although
both antibodies were immunoreactive in permeabilized cells,
only the Myc antibody positively stains the membranes of live
cells, whereas the His6 antibody does not, suggesting that the
RPS23R1 N terminus is extracellular (Figure 4E). Hence these
results suggest that RPS23R1 is a type Ib transmembrane
protein that has a normal type I transmembrane protein orienta-
tion but no cleavable signal peptides. Immunoprecipitation
combined with live immunostaining also confirmed the type Ib
transmembrane topology of RPS23R1 (Figure S2). We derived
an antibody against the N terminus of RPS23R1 (Figure S3)Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc. 331
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brane Protein
(A) Scheme of the RPS23R1 construct used in this
study (not drawn to proportion), with a Myc tag at
the N terminus and a His6 tag at the C terminus.
RPS23R1 has a predicted single transmembrane
domain (TM) near its C terminus.
(B) The Myc-RPS23R1-His6 vector (RR1) or a
pcDNA control (Con) was transiently transfected
into N2a cells. Cell lysates were subjected to
western blot (WB) with antibodies against Myc or
His6.
(C) RPS23R1 (RR1), APP, and SMAD3 plasmids
(all Myc tagged) were individually transfected into
N2a cells. After fractionation of membrane and
cytosol, equal volumes of samples from both frac-
tions were subjected to SDS-PAGE and western
analysis with a Myc antibody. *nonspecific band.
(D) After RPS23R1 transfection, N2a cells were
biotinylated and biotin-labeled membrane pro-
teins were affinity precipitated (AP) with streptiva-
din and immunoblotted with a Myc antibody.
(E) After transfection with the Myc-RPS23R1-His6
construct, N2a cells were either live immuno-
stained or permeabilized and immunostained
with Myc or His6 antibody. Cells were then fixed,
permeabilized, incubated with Alexa Fluor 488-
conjugated secondary antibody and DAPI, and
examined by immunofluorescence microscopy.
Red arrows indicate membrane staining of
RPS23R1 in live cells.
(F) Equal protein lysates from mouse cortex and
hippocampus (hippo) were incubated with an
RPS23R1 antibody (+) or rabbit IgG (). After
immunoprecipitation, samples were subjected to
SDS-PAGE and western blot analysis with the
RPS23R1 antibody.
(G) An antisense probe of Rps23r1 and the corre-
sponding sense probe (as control) were used for
in situ hybridization in brain sections from a two-
month-old C57Bl6 mouse. Red arrows indicate
Rps23r1 expression.and using this antibody for immunoprecipitation followed by
western blot analysis, we confirmed expression of RPS23R1 in
both cortex and hippocampus (Figure 4F). In situ hybridization
analysis of Rps23r1 expression in mouse brain revealed that
Rps23r1 is expressed primarily in hippocampus, dentate gyrus,
and cortex (Figure 4G).
RPS23R1 Overexpression Reduces Ab Levels, GSK-3
Activity, and Tau Phosphorylation
The FG01 RHGP cell clone exhibits increased APP bCTF accu-
mulation and reduced Ab levels (Figure 2C), suggesting that
RPS23R1 regulates APP processing. To corroborate this, we
overexpressed RPS23R1 in N2aSwe cells. The results showed
that, although the levels of total APP were not affected, the levels
of extracellular and intracellular Ab were significantly reduced by
RPS23R1 overexpression, and the levels of bCTF and sAPPa
were significantly increased (Figure 5A). When human HeLa cells
stably expressing the human APP Swedish mutation (HeLaSwe)
were transfected with mouse RPS23R1, we also observed
reduced Ab levels and increased accumulation of bCTF and332 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.sAPPa (Figure 5A). ELISA analysis confirmed that both Ab40
and Ab42 levels were significantly reduced following RPS23R1
expression in HeLaSwe cells (Figure 5B). These data demon-
strated that mouse RPS23R1 can function not only in mouse
cells, but also in human cells.
To determine whether RPS23R1 reduces Ab levels by
modulating b-secretase activities, we examined b-secretase
(BACE1) activity and the protein level of BACE1 in vitro in
RPS23R1-overexpressing cells and found them both unchanged
(Figures S4A and S4B). APP bCTF accumulation can also be
attributed to a decrease in g-secretase-mediated cleavage.
However, cleavage of Notch, another important g-secretase
substrate (Kopan and Goate, 2000), was not altered by
RPS23R1 overexpression (Figure S4C). Protein levels of nicas-
trin, an important component of the g-secretase complex, and
ADAM10 and TACE, two putative a-secretases (Zhang and Xu,
2007), were also not affected by RPS23R1 overexpression
(Figure S4B).
Although the possibility that RPS23R1 may modulate
substrate specificity or accessibility to g-secretase cannot be
Neuron
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GSK-3 Activity, and Tau Phosphorylation
(A) RPS23R1 (RR1) or control vector (Con) were
transfected into mouse N2aSwe or human
HeLaSwe cells. Ab in conditioned media (secreted
or extracellular) and in cell lysates (intracellular)
was immunoprecipitated and western blotted
with the Ab antibody 6E10. sAPPa in conditioned
media was immunoblotted with 6E10. Cell lysates
were immunoblotted with antibodies against APP/
bCTF (6E10), phosphorylated GSK-3a/b, total
GSK3a/b, and Myc-RPS23R1 (9E10).
(B) ELISA quantification of Ab40 and Ab42 levels in
conditioned media and lysates of HeLaSwe cells
with RPS23R1 (RR1) overexpression. Results
were normalized to that of Ab40 in conditioned
media (set as 100). Ab42 in cell lysates was below
detection level and not shown.
(C) GSK-3a and GSK-3b in lysates from N2aSwe
cells transfected with control or RPS23R1 vector
were immunoprecipitated with respective anti-
bodies and assayed for in vitro activity. Results
were normalized to those of controls (set as one
arbitrary unit).
(D) N2aSwe cells were first transfected with
RPS23R1 (RR1) or control vector (Con). After
equal splitting, cells were treated with 5 mM LiCl
or NaCl (as control) for 4 hr before collection.
Conditioned media were assayed for Ab. Cell
lysates were analyzed for total and phosphory-
lated GSK-3a/b and for RPS23R1.
(E) N2a cells were transfected with human tau,
equally split, and transfected with RPS23R1
(RR1) or control vector (Con). The levels of phos-
phorylated tau including threonine 205 (pT205)
and PHF-1, unphopshorylated tau (Tau-1), total
tau, and RPS23R1 were analyzed.
In some experiments, protein levels were quanti-
fied by densitometry and normalized to those of
controls for comparison (set as one arbitrary
unit). Error bars indicate SEM *p < 0.05, **p <
0.01. p values were calculated using two-tailed
Student’s t test (n = 3).excluded, it is equally possible that RPS23R1 regulates other
proteins/pathways functioning in APP processing and Ab gener-
ation. One of those could be GSK-3, which has been shown to
affect Ab generation (without affecting g-secretase-mediated
Notch cleavage) and tau phosphorylation (Phiel et al., 2003;
Takashima et al., 1995). Thus, we studied the activities of
GSK-3a/b in the presence or absence of RPS23R1 overexpres-
sion by examining levels of phospho-GSK-3a (Ser 21) and
phospho-GSK-3b (Ser 9) (which represent inactivated forms of
GSK-3) and by in vitro kinase assays. In cells overexpressing
RPS23R1 we observed that GSK-3a/b was more highly phos-
phorylated at these sites in mouse N2aSwe (Figure 5A), rat
PC12 (data not shown), and human HeLaSwe (Figure 5A) and
HEK293 (data not shown) cells, indicating that RPS23R1 can
decrease GSK-3 kinase activity in cells of various types and
species including human. In vitro kinase assays also demon-
strated an approximately 50% decrease in GSK-3a and a 40%decrease in GSK-3b activities in RPS23R1-overexpressing cells
(Figure 5C). Remarkably, in the presence of lithium, a general
inhibitor of both GSK-3a and GSK-3b, RPS23R1 overexpression
could not further reduce GSK-3a/b activity or Ab production
(Figure 5D). These data suggest that RPS23R1 reduces Ab levels
by downregulating GSK-3 activity.
GSK-3 is a major kinase that phosphorylates tau in AD (Flah-
erty et al., 2000). Hence, we asked whether RPS23R1 affects
tau phosphorylation by inhibiting GSK-3. We cotransfected
N2aSwe cells with the human tau splice variant T40 and with
RPS23R1 (or control vectors) and examined tau phosphorylation
at the threonine 205 site (pT205) and the PHF-1 tau epitope sites
(serine 396 and serine 404), which are GSK-3 phosphorylation
targets and the major paired helical filament (PHF) sites found
in NFTs. Overexpression of RPS23R1 significantly decreased
tau phosphorylation at these GSK-3 target sites and increased
unphosphorylated tau levels without affecting total tau levelsNeuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc. 333
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Rps23r1 Ameliorates AD-like PathologiesFigure 6. RPS23R1 Interacts with Adenylate
Cyclases, Upregulates cAMP Levels, and
Activates PKA to Reduce GSK-3 Activity
and Ab Levels
(A) Cells transfected with RPS23R1 or control
vector (Con) were analyzed for in vitro PKA activity.
Results were normalized to control values (set as
one arbitrary unit).
(B) After transfection with RPS23R1 (RR1) or
control vector (Con) and equal splitting, cells
were treated with DMSO (control) or the PKA inhib-
itor H89. Conditioned media were analyzed for
Ab and cell lysates were analyzed for phosphory-
lated and total CREB, phosphorylated and total
GSK-3, and RPS23R1 levels.
(C) N2aSwe cells were transfected with Rps23r1-
specific RNAi or a scrambled RNAi (SC). Total
RNA was then extracted and subjected to
RT-PCR. The mRNA level of Rps23r1 relative
to that of b-actin was analyzed and normalized
to that from scrambled RNAi-transfected cells
(set as one arbitrary unit).
(D) After RNAi ofRps23r1 (RR1) expression, condi-
tioned media from N2aSwe cells were analyzed for
Ab, and cell lysates were analyzed for endogenous
RPS23R1 and phosphorylated/total CREB and
GSK-3.
(E) Mouse N2a and rat PC12 cells were transfected
with RPS23R1 or control vector (Con), and cell
lysates were assayed for cAMP levels. Data were
normalized to control values (as one arbitrary unit).
(F) Cells transfected with RPS23R1 or control
vector (Con) were lysed in 1% CHAPSO or 1%
NP40 buffer. Lysates were incubated with mouse
IgG (mIgG), rabbit IgG (rIgG), Myc antibody, or
adenylate cyclase antibody. Immunoprecipitated
proteins were subjected to SDS-PAGE and
western blot analysis with adenylate cyclase or
Myc (for RPS23R1) antibodies.
In some experiments, protein levels were quanti-
fied by densitometry and normalized to those of
controls for comparison (set as one arbitrary
unit). Error bars indicate SEM. *p < 0.05, **p <
0.01. p values were calculated using two-tailed
Student’s t test (n = 3).(Figure 5E). These results suggest a role for RPS23R1 in reducing
tau phosphorylation, in addition to its effect on Ab levels. We also
analyzed protein levels and activity of CDK5, another kinase
mediating tau phosphorylation in AD (Flaherty et al., 2000),
following RPS23R1 overexpression and observed little change,
suggesting that CDK5 is not involved in RPS23R1-regulated
tau phosphorylation (Figure S5).
RPS23R1 Interacts with Adenylate Cyclases to
Upregulate cAMP Levels and PKA Activity
Inhibition of GSK-3 activity via phosphorylation of serine 21 in
GSK-3a and serine 9 in GSK-3b can be mediated by protein
kinase A (PKA) (Fang et al., 2000), so we studied whether
RPS23R1 regulates PKA activity. In vitro kinase assays revealed
that RPS23R1-transfected cells had significantly more PKA
activity than control cells (Figure 6A), consistent with the obser-
vation that RPS23R1 overexpression increased phosphorylation
of CREB, a PKA substrate (Figure 6B). In addition, RPS23R1334 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.failed to inhibit GSK-3 activity and Ab generation when PKA
activity was suppressed by the specific inhibitor H89 (Figure 6B).
Furthermore, downregulation of endogenous RPS23R1 expres-
sion in N2aSwe cells by RNA interference (Figures 6C and 6D)
dramatically reduced CREB phosphorylation, and increased
GSK-3 activity and Ab generation (Figure 6D). These data indi-
cate that RPS23R1’s effects on GSK-3 activity and Ab levels
require PKA activation. Moreover, increased sAPPa secretion
upon RPS23R1 overexpression (Figure 5A) is also likely due to
PKA activation, because PKA can stimulate budding of APP-
containing vesicles from the trans-Golgi network (TGN) to cell
surface, the major site for APP cleavage by a-secretase, there-
fore facilitating sAPPa generation (Xu et al., 1996).
Since cAMP binds to and activates PKA (Taylor et al., 2008),
we investigated whether RPS23R1 overexpression had any
effect on cAMP levels. We found that RPS23R1 overexpression
significantly increased cAMP levels in both mouse N2a (38%)
and rat PC12 (75%) cells (Figure 6E). We next examined potential
Neuron
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responsible for cAMP synthesis (Kamenetsky et al., 2006).
Coimmunoprecipitation studies showed that RPS23R1 interacts
with both overexpressed (data not shown) and endogenous
(Figure 6F) adenylate cyclases in N2a cells overexpressing
RPS23R1, suggesting a possible modulation of enzymatic
activity for cAMP production.
To confirm that it is indeed the RPS23R1 protein rather than
the Rps23r1 mRNA that mediates these effects, we constructed
an RPS23R1 mutant vector with a stop codon at the beginning of
the protein-coding region. Cells transfected with this mutant
vector showed mRNA expression (detected by RT-PCR) but no
protein expression of the mutant RPS23R1 (Figure S6). In addi-
tion, overexpression of this mutant RPS23R1 did not affect the
activity of PKA or GSK-3, or Ab levels (Figure S6), excluding
any potential RNA interfering effects arising from anti-sense
interaction with Rps23 RNA.
Overexpression of RPS23R1 Reduces Ab Levels, GSK-3
Activity, and Tau Phosphorylation in the Brain of
the Triple Transgenic AD Mice
To validate RPS23R1 function in vivo, we generated an Rps23r1
transgenic mouse model specifically overexpressing Myc-
tagged RPS23R1 in the brain. A transgenic expression cassette
driven by the human Thy-1 promoter (Figure S7A) was microin-
jected into C57Bl6 mice and we used primers specifically
amplifying exogenous Rps23r1 to genotype transgenic mice
(Figure S7B). Reverse transcription-PCR revealed that mRNA
of the exogenous gene was indeed expressed in transgenic
mouse brains (Figure S7C). Protein expression of exogenous
Myc-tagged RPS23R1 was also confirmed in brain tissues of
transgenic mice (Figure S7D). In addition, immunoprecipitation/
western blot showed that total (including exogenous and endog-
enous) protein levels of RPS23R1 in the transgenic mice were
about 2-fold higher than endogenous RPS23R1 levels in control
mice (Figure S7E). We generated two mouse lines with similar
RPS23R1 expression levels and results obtained from the two
lines (including their crossing with 3XTg mice as described
below) were similar. Herein we only presented results from line
2. Our results showed that levels of phosphorylated and there-
fore inactive GSK-3a/b were increased (Figure S7D), accompa-
nied by reduced GSK-3b activity in Rps23r1 transgenic mouse
brain (Figure S7F). Increased CREB phosphorylation indicative
of upregulated PKA activity, as well as decreased phosphoryla-
tion of endogenous mouse brain tau, was also seen in Rps23r1
transgenic mouse brain (Figure S7D). In addition, preliminary
observation detected no obvious aberrant behavioral pheno-
types in Rps23r1 transgenic mice (data not shown).
We next crossed Rps23r1 transgenic mice with triple trans-
genic (3XTg) AD mice harboring mutations in human App
(APP), Mapt (tau), and Psen1 (presenilin 1) genes (Oddo et al.,
2003). As expected, RPS23R1 overexpression in 3XTg mice
dramatically increased the levels of cAMP and PKA activity
(Figure S8A), resulting in elevated CREB activity, and reduced
GSK-3 activity, tau phosphorylation, and Ab levels in mouse
brains (Figures 7A and S8B). Consistently, the numbers of both
Ab-immunostaining-positive (by Ab40-specific antibody and
6E10 antibody) and phosphorylated tau-immunostaining-posi-tive (by PHF-1 and pT205 antibodies) neurons in the 3XTg
mouse brain (both hippocampus and cortex) were significantly
decreased following RPS23R1 overexpression (Figures 7B, 7C,
7E, S8C, S8D, and S8F). Interestingly, protein levels of the
synaptic marker PSD-95 were markedly increased following
RPS23R1 overexpression in 3XTg mouse brains (Figure 7A).
Immunostaining of PSD-95 (Figures 7D and 7E) and synapsin
(Figures S8E and S8F), another synaptic marker, also revealed
significantly higher immunoreactivity in the hippocampus of
3XTg mouse brains with RPS23R1 overexpression than that
seen in 3XTg mice without RPS23R1. These results imply that
RPS23R1 may rescue synapse impairment seen in 3XTg mice
(Oddo et al., 2003), in addition to, or as a consequence of, its
effects on reducing Ab generation and tau phosphorylation.
Consistent with the results found in cell cultures (Figure S4B),
protein levels of ADAM10 and TACE were not affected by
RPS23R1 overexpression in the brain of 3XTg mice (Figure 7A).
Caloric restriction and environmental enrichment have been
shown to reduce AD-like pathologies and behavior deficits in
animal models (Halagappa et al., 2007; Lazarov et al., 2005).
Since elevated CREB activity in the brain may affect animal
behaviors such as food intake and daily activity, we compared
body weight of RPS23R1-overexpressing mice to that of control
mice and found no difference at 3 months of age. At 7 and
11 months of age, we noticed that RPS23R1-overexpressing
mice are slightly (but not significantly) lighter than controls
(data not shown), even though visual inspection of daily activity
and food intake between these mice showed no obvious differ-
ences. Therefore, there is a possibility that RPS23R1 exerts its
effect on alleviating AD-like pathologies by altering mouse
behaviors and this possibility deserves further investigation.
DISCUSSION
Using the RHGP assay to screen for genes involved in regulating
Ab generation, we identified the functional retroposed Rps23r1
gene on mouse chromosome 8. The RPS23R1 protein is a type
Ib transmembrane protein and is expressed in the brain. In the
present report, we provide compelling evidence to show that
RPS23R1 overexpression can reduce both Ab levels and tau
phosphorylation, two major pathological hallmarks of AD. We
also reveal the underlying mechanism, i.e., RPS23R1 interacts
with adenylate cyclases to upregulate cAMP levels, which acti-
vates PKA activity, hence inhibiting GSK-3 activity, tau phos-
phorylation, and Ab generation. These results elucidate an
important link between adenylate cyclases and AD, which had
not been illustrated previously.
Sequence analyses demonstrated that Rps23r1 originated
through retroposition of mouse Rps23, which recruited regula-
tory units and additional protein encoding fragments at the retro-
position site and became functional (Figure 3A). The reversal in
transcriptional direction of Rps23r1 relative to the parental
Rps23 gene explains why there is no protein sequence similarity
between RPS23R1 and RPS23. Rps23 belongs to the ribosomal
protein family and is highly conserved among species (Hori et al.,
1993). Since human ribosomal protein genes have been found to
generate a large number of processed pseudogenes through ret-
roposition (Zhang et al., 2002), there is a possibility that humanNeuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc. 335
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Rps23r1 Ameliorates AD-like PathologiesFigure 7. RPS23R1 Overexpression Increases PKA Activity and Synapse Number and Reduces GSK-3bActivity, Tau Phosphorylation, and Ab
Levels in Brains of 3XTg AD Mice
(A) Brains from Rps23r1 transgenic mice and littermate controls (Con) on a 3XTg background at 11 months of age were dissected. One-half of the brain was lysed
and analyzed for the levels of phosphorylated/total CREB, phosphorylated/total GSK-3, PSD-95, ADAM10, TACE, a-tubulin, and phosphorylated (PHF-1) and
total tau forms by direct western blot. Ab and Myc-RPS23R1 were detected by immunoprecipitation-western blot using Ab antibody (6E10) and Myc antibody,
respectively. *nonspecific band found specifically in 3XTg mouse brains.
(B) The other half-brain from Con (I and III) andRps23r1 transgenic (II and IV) mice was analyzed by immunohistochemistry for Ab using an Ab40-specific antibody.
III and IV are higher magnifications of cortical regions from I and II, respectively. Red arrows indicate positive immunoreactivity.
(C) Immunohistochemistry for phosphorylated tau (PHF-1 tau) was analyzed the same as in (B). Red arrows indicate positive immunoreactivity.
(D) Immunohistochemistry for PSD-95 was analyzed the same as in (B), except that III and IV are higher magnifications of hippocampal regions from I and II,
respectively.
(E) Immunostained neurons (>400) in (B) and (C) were counted from five randomly selected cortical regions. Ratios of Ab40-positive and PHF-1 tau-positive
neurons to total neurons were determined and normalized to those of control (Con) for comparison. The optical density (darkness) of PSD-95 staining in five
randomly selected hippocampal regions were analyzed by the Photoshop software for comparison. *p < 0.05. p values were calculated using two-tailed Student’s
t test (n = 4). Error bars, SEM.336 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.
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functional genes with orientations and functions similar to those
of Rps23r1. However, although we indeed identified several
human Rps23 retroposition sites in the human genome
(Figure S1), neither computational gene prediction nor RT-PCR
with primers binding adjacent regions of these human Rps23
retroposition sites has so far revealed any Rps23r1-like genes
(data not shown). More extensive efforts are needed for
screening functional Rps23r1 homologs in humans.
During aging, humans are susceptible to AD pathogenesis,
typically characterized by Ab overproduction/aggregation and
tau hyperphosphorylation. In contrast, wild-type mice rarely
develop AD pathologies (De Strooper et al., 1995; Jankowsky
et al., 2007; Johnstone et al., 1991). The differences in AD
susceptibility between humans and mice have been attributed
to the sequence disparity between human and mouse Ab (and
possibly tau) that underlie different aggregation properties (De
Strooper et al., 1995; Jankowsky et al., 2007; Johnstone et al.,
1991), to the short lifespan of mice relative to humans (Jankow-
sky et al., 2004; Jankowsky et al., 2007) and to the differences in
processing of human and mouse APP by BACE1 (Cai et al.,
2001). Should humans lack Rps23r1 homologs, our results
would provide an alternative explanation, i.e., some genetic
factors in mice, such as Rps23r1, protect them against an
AD-like disease by preventing Ab over-production and tau
hyperphosphorylation.
On the other hand, mouse RPS23R1 also exerts its functions in
human cells, suggesting that RPS23R1-mediated signaling
pathways are active in humans. Further scrutiny of these
pathways, especially upstream events involving RPS23R1’s
effects on adenylate cyclases, is critical and underway. While it
is not yet known whether there are functional homologs of
RPS23R1 in humans, further elucidation of RPS23R1 functions
and mechanism of action may prove to be important for devel-
oping new strategies for combating AD and other diseases
including cancer and diabetes, in which the PKA and GSK-3
signaling pathways are centrally involved (Martinez et al., 2002;
Naviglio et al., 2009).
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents
Maintenance of mouse neuroblastoma N2a cells, N2a cells stably expressing
human APP Swedish mutation (N2aSwe), human HeLa cells stably expressing
human APP Swedish mutation (HeLaSwe), and rat PC12 cells has been
described (Lin et al., 2007; Wang et al., 2006; York et al., 2000). Phoenix-
Ampho helper cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. Antibodies used were: anti-Myc
(9E10), anti-adenylate cyclases, anti-His, anti-ADAM10, and anti-TACE from
Santa Cruz Biotechnology; anti-GSK-3a, anti-GSK-3b, anti-phospho-GSK-
3a/b (Ser21/9), anti-CREB, anti-phospho-CREB (Ser 133), anti-PSD-95, and
anti-synapsin from Cell Signaling Technology; anti-Ab40, anti-pT205 tau and
anti-total tau from Abcam; anti-Ab (6E10) from Covance; anti-tau-1 from
Chemicon; anti-a-tubulin from Sigma; anti-PHF-1 tau from P. Davies at Albert
Einstein School of Medicine; and the FCA18 antibody specifically recognizing
the N terminus of APP bCTF from F. Checler at Institut de Pharmacologie
Molecularie et Cellulaire du CNRS (Ancolio et al., 1999). The rabbit polyclonal
antibody 369 against the APP C terminus (Xu et al., 1997) and the anti-
RPS23R1 antibody were developed in our laboratory. PKA inhibitor H89 and
GSK-3 inhibitor lithium chloride were from Sigma.Random Homozygous Gene Perturbation (RHGP) Strategy
for Screening Ab-Reducing Genes
We constructed a new RHGP gene search vector from the original pLLGSV
vector (Li and Cohen, 1996). In the 30LTR region of the new RHGP gene search
vector, there is a sequence containing a puromycin N-acetyl-transferase gene
(Pac), a TRE (tetracycline-regulated element, tet-off) regulated CMV promoter
driving the Pac gene, a plasmid replication origin and a chloramphenicol resis-
tance marker (Ori-CAT), and a LoxP site. In addition, there is a Cre recombi-
nase gene (Cre) between the 50LTR and the 30LTR (Figure 1A). This new
RHGP gene search vector was transfected into Phoenix-Ampho help cells.
Generated infectious retrovirus in the cell culture supernatant was harvested
and used to infect N2aSwe cells.
The infected N2aSwe cells with RHGP vector integration were selected with
puromycin, live-stained with fluorescence-labeled APP bCTF antibody FCA18
(Ancolio et al., 1999), and subjected to multiple rounds of FACS sorting for cells
with accumulated cell surface APP bCTF. The positive-sorted cells were then
treated with doxycycline (a derivative of tetracycline) and sorted for cells
whose surface APP bCTF level was reversed back to background level in
the presence of doxycycline. Resultant cells were cloned individually and
assayed by ELISA and western blotting to confirm surface accumulation of
APP bCTF and reduction of Ab generation. Positive candidate cell clones
were further characterized and used for gene isolation.
Rps23r1 Gene Cloning
Genomic DNA was extracted from the FG01 RHGP cell clone, digested with
restriction enzyme BamHI or HindIII, and self-ligated overnight with T4 ligase.
The ligated DNA was precipitated, dissolved in TE buffer and electroporated
into DH10B ElectroMax competent cells. The plasmid DNA from individual
colonies was prepared for DNA sequencing. The target gene was identified
by using UCSC Genome Browser Program.
Sequence Analyses
We blasted GenBank database with Rps23r1 cDNA sequence to explore its
origin. Homologous sequences between Rps23r1 and mouse Rps23 were
aligned manually. Sequence similarity betweenRps23r1 andRps23 sequences
of humans, mice and rats were compared using their homologous regions.
Potential transmembrane region in the RPS23R1 protein was predicted using
PredictProtein (Rost et al., 2004).
Membrane Fractionation
N2a cells were transfected with RPS23R1, APP, or SMAD3 expression vectors
(all Myc tagged). After 48 hr, cells were washed with ice-cold phosphate-buff-
ered saline, collected with homogenization buffer (10 mM Tris-HCl [pH 7.4],
1 mM EDTA, 200 mM sucrose, 1 mM phenylmethylsulfonyl fluoride) and
homogenized with a ball bearing cell cracker. Samples were centrifuged at
9003 g for 10 min to remove cell debris and nuclei. Supernatants were centri-
fuged at 100,000 3 g for 60 min at 4C. After transferring the supernatant
(cytosol) to a new tube, the pellet was washed and resuspended with an equal
volume (to that of cytosol) of homogenization buffer.
Biotinylation
RPS23R1 transfected N2a cells were washed with ice-cold phosphate-buff-
ered saline containing 1 mM each of CaCl2 and MgCl2 and incubated at 4
C
with 0.5 mg/ml Sulfo-NHS-LC-biotin (Pierce) for 20 min and the process
repeated once. Cell lysates were prepared in Nonidet P-40 lysis buffer. After
affinity precipitation with streptavidin beads (Pierce), biotinylated proteins
were eluted with SDS-PAGE sample buffer (Invitrogen) and loaded directly
on SDS-PAGE gels for electrophoresis followed by western blot analysis
with the Myc antibody.
Immunofluorescence Microscopy
For cell surface immunostaining of RPS23R1, N2a cells were first transfected
with the Myc-RPS23R1-His6 plasmid. Cells were then directly incubated with
Myc or His6 antibody at 4C for 2 hr, followed by washing, fixation, and perme-
abilization. In some experiments, cells were permeabilized before incubating
with antibodies. Treated cells were incubated with Alexa Fluor 488-conjugated
secondary antibody and DAPI. Specimens were examined and fluorescenceNeuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc. 337
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software.
Ab ELISA Assay
HeLaSwe cells were transfected with RPS23R1 or control vector. Conditioned
media and lysates from these cells were collected. The levels of Ab40 and
Ab42 were quantified using ELISA kits (Invitrogen), following the manufac-
turer’s protocols.
Pharmacological Treatments
N2aSwe cells were transfected with control vector or RPS23R1 and then
equally split. Four hours before collection, cells were treated with the GSK-3
inhibitor lithium chloride (5 mM) or sodium chloride (5 mM, as control). Alterna-
tively, cells were treated with a PKA inhibitor H89 (10 mM) or with DMSO for
control.
Rps23r1 RNA Interference and Quantitative Real-Time PCR
The mouse Rps23r1 siRNA used was: 50-UACUGUUUGUCAUGCCACUUCU
GAU-30. The control siRNA was from Invitrogen. siRNA was transfected into
N2a cells using Lipofectamine RNAiMAX reagent (Invitrogen), following the
manufacturer’s protocol. After Rps23r1 RNA interference, total RNA was
extracted from N2a cells by Trizol reagent (Invitrogen). After reverse transcrip-
tion into first strand cDNA using standard conditions, samples were analyzed
independently by real-time PCR using an iCycler iQ with SYBR green supermix
(Bio-Rad). The Rps23r1 primer pair used for real-time PCR was: Rps23r1-50
(50-TGTTGCATACACATACATGC-30) and Rps23r1-30 (50-TCATTAAGAACGG
GAAGAAG-30). A pair of b-actin primers served as controls (Zhang et al., 2007).
In Situ Hybridization
Histological sections from 2-month-old C57Bl6 mice were used for in situ
hybridization reactions. Digoxygenin-labeled sense and antisense probes
were generated for Rps23r1 (corresponding to nucleotides 1–641 of
NM_001024728), and the hybridization signal was detected using an alka-
line-phosphatase-conjugated anti-digoxygenin antibody and BCIP/NTB
(Roche).
Crossing Brain-Specific Rps23r1 Transgenic Mice with 3XTg AD
Mice
We generated brain-specific Rps23r1 transgenic mice (Figure S7). Hemizy-
gous Rps23r1 transgenic mice were crossed with homozygous triple trans-
genic (3XTg) AD mice harboring mutations in human App and Mapt (tau) genes
on a presenilin 1 (PS1) mutant background (Oddo et al., 2003). Procedures
involving animals and their care conformed to institutional guidelines (Animal
Resources Department at Burnham Institute for Medical Research).
Immunohistochemistry and Data Analyses
Rps23r1/3XTg mice and littermate controls on a 3XTg background were
sacrificed at 11 months of age. Half of the brain was used for immunoblot anal-
ysis and the other half was paraffin embedded for immunohistochemistry.
Coronal brain sections (4 mm) were deparaffinized, hydrated, and then
immunostained with anti-Ab antibodies (an anti-Ab40 specific antibody and
6E10), anti-phosphorylated tau antibodies (PHF-1 and pT205), or antibodies
against PSD-95 and synapsin. After additional incubation with biotinylated
secondary antibody, samples were incubated in ABC Elite (HRP) reagent
(Vector Laboratories). Reactions were visualized by developing in DAB
substrates (Vector Laboratories). All samples were visualized under a light
microscope.
For immunohistochemistry comparison of Ab and tau, immunostained
neurons (>400) were counted from five randomly selected cortical regions.
Ratios of Ab-positive and phosphorylated tau-positive neurons to total
neurons were determined and normalized to those of controls. For immunohis-
tochemistry comparison of synapse markers, five hippocampal regions were
randomly selected and the images captured. After converting the images to
grayscale, the optical density (darkness) of molecular layer staining was
measured as an average of the gray value between white (0) and black (255)
as described (Mathern et al., 1997) for comparison, by a computer-based
image analysis using the Photoshop software.338 Neuron 64, 328–340, November 12, 2009 ª2009 Elsevier Inc.In Vitro Activity Assays and cAMP Assay
Commercial kits were used to assay in vitro activities of GSK-3b (Sigma) and
PKA (Upstate). For GSK-3a activity, a commercial GSK-3b activity assay kit
was used but the procedure to immunoprecipitate GSK-3b was replaced
with immunoprecipitation of GSK-3a using an anti-GSK-3a antibody (Cell
Signaling). cAMP levels were assayed using a commercial kit (Biovision).
Coimmunoprecipitation
Cells transfected with RPS23R1 were lysed in either CHAPSO buffer (1%
CHAPSO, 25 mM HEPES [pH 7.4], 150 mM NaCl, and 2 mM EDTA supple-
mented with protease inhibitors) or in NP40 buffer (1% Nonidet P-40 in phos-
phate buffered saline, supplemented with protease inhibitors). Lysates were
immunoprecipitated using mouse IgG, rabbit IgG, and antibodies against
Myc or adenylate cyclases and Trueblot IP beads (eBioscience), followed by
western blot with antibodies against Myc or adenylate cyclases.
SUPPLEMENTAL DATA
Supplemental Data include eight figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.com/
neuron/supplemental/S0896-6273(09)00674-6.
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